Centogene N.V. (Nasdaq: CNTG), the essential life science partner
for data-driven answers in rare and neurodegenerative diseases,
today announced it has extended its partnership with Takeda (TSE:
4502/NYSE: TAK) to diagnose patients with Lysosomal Storage
Disorders (LSDs).
Under the renewed one-year partnership agreement, CENTOGENE will
continue to provide Takeda with access to diagnostic testing for
patients around the world. The aim of the commercial
fee-for-service agreement is to enhance patient access to rapid and
reliable diagnostics for LSDs, including Fabry disease, Gaucher
disease, and Hunter syndrome.
“We are excited to extend our partnership with Takeda to
accelerate diagnosis and increase access to life-saving
therapeutics for patients globally,” said Ian Rentsch, CENTOGENE
Chief Commercial Officer and General Manager - Pharma. “Leveraging
our targeted diagnostic portfolio, network of over 30,000 active
physicians, and the CENTOGENE Biodatabank driving novel insights,
we are uniquely positioned to deliver substantial value to our
pharma partners throughout every stage of the development pipeline.
This collaboration continues to play a vital role in the expansion
of Takeda’s world-class enzyme replacement treatments and most
importantly, brings life-changing answers to underserved patient
communities.”
A key asset to the partnership is the CENTOGENE Biodatabank,
which currently contains approximately 700,000 patients
representing over 120 highly diverse countries, more than 70% of
whom are of non-European descent, including a large share of
pediatric cases. By integrating multiomic and multi-ethnic data,
the CENTOGENE Biodatabank captures a holistic view to enable the
most accurate diagnosis and guide clinical actions.
In January 2015, CENTOGENE originally entered into an agreement
with Shire Pharmaceuticals, which was acquired in 2019 by Takeda,
to provide diagnostic testing capability to enhance early diagnosis
of patients suffering from rare genetic diseases. Last year, the
contract was extended until March 2023.
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with nearly
700,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 260 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target & drug screening, clinical
development, market access and expansion, as well as offering
CENTOGENE Biodata Licenses and Insight Reports to enable a world
healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward- looking
statements. Such risks and uncertainties include, among others,
negative economic and geopolitical conditions and instability and
volatility in the worldwide financial markets, possible changes in
current and proposed legislation, regulations and governmental
policies, pressures from increasing competition and consolidation
in our industry, the expense and uncertainty of regulatory
approval, including from the U.S. Food and Drug Administration, our
reliance on third parties and collaboration partners, including our
ability to manage growth, execute our business strategy and enter
into new client relationships, our dependency on the rare disease
industry, our ability to manage international expansion, our
reliance on key personnel, our reliance on intellectual property
protection, fluctuations of our operating results due to the effect
of exchange rates, our ability to streamline cash usage, our
continued ongoing compliance with covenants linked to financial
instruments, our requirement for additional financing, or other
factors. For further information on the risks and uncertainties
that could cause actual results to differ from those expressed in
these forward-looking statements, as well as risks relating to
CENTOGENE’s business in general, see CENTOGENE’s risk factors set
forth in CENTOGENE’s Form 20-F filed on March 31, 2022, with the
Securities and Exchange Commission (the “SEC”) and subsequent
filings with the SEC. Any forward-looking statements contained in
this press release speak only as of the date hereof, and
CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Contact:
CENTOGENE
Ben Legg Corporate
Communications Press@centogene.com
Lennart StreibelInvestor RelationsIR@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Jul 2023 to Jul 2024